WG1: Particle engineering/processing of inhaled medicines for local/systemic action
-
Identify optimal deposition sites for topical and systemic therapies.
-
Consolidate information on the effects of lung disease on the deposition-dissolution-absorption pathway.
-
Asses the effect of airway geometrical differences on regional deposition patterns and identify key effects to be included in CFPD simulations.
-
Promote deeper understanding of dissolution and absorption in the alveolar region.
-
Assess emerging nanomedicine and excipient technologies in terms of efficiency and safety.
-
Train ECIs and other interested scientists in emerging particle-engineering technologies and promote the acquisition of intra-disciplinary skills (simulations, imaging, toxicity) by ECIs who are already experts in particle engineering.
WG2: Device engineering and formulation-aware inhaler design
-
Promote the integrated design of formulations and inhaler devices.
-
Consolidate understanding on the balance of interparticulate dispersion-deposition forces for various formulation-inhaler designs by leveraging ongoing research and CFPD simulations.
-
Identify best design practices for emerging formulation needs such as high-dose drugs and combination therapies, taking into account cost and safety.
-
Promote the development of customized formulation-inhaler designs for special patient groups, such as the elderly and young children.
-
Promote STSMs to and from participating inhaler manufacturers, especially for ECIs.
WG3: Computer simulations as a horizontal enabling technology: delivery, deposition and lung-tissue/particles interaction
-
Promote close interaction between CFPD, medical imaging and pharmaceutics experts.
-
Establish best-practice guidelines for the current generation of CFPD simulations tools that will be accessible to non-CFPD experts
-
Identify and prioritize additional physical effects that must be included in CFPD tools to make simulations more realistic.
-
Establish a roadmap leading to integrated multiscale simulations with the ability to track aerosols over the entire delivery pathway.
-
Establish a roadmap leading to patient-specific and patient-class-specific CFPD simulations.
-
Promote the utilization of emerging functional pulmonary imaging technologies for the validation and verification of computational models.
-
Promote the role of CFPD as a Quality-by-Design tool.
WG4: Advanced imaging, patient monitoring and delivery verification
-
Assess the relative merits and challenges associated with emerging imaging technologies.
-
Establish realistic pathways for the leveraging of emerging imaging technologies in the their current state of development for simulation validation, R&D enhancement and patient monitoring.
-
Promote deeper understanding of dissolution and absorption in the alveolar region through the utilization of emerging function imaging methods.
-
Promote deeper understanding of regional deposition and clearance in the conducting airways through the utilization of emerging functional imaging methods.
-
Train ECIs and other interested scientists on emerging functional imaging technologies.
WG5: Toxicity, xenobiotics, risk assessment and policy development
-
Establish the factors that affect dosimetry in toxicity studies for inhaled medicines.
-
Identify test systems (in vitro, in vivo, in silico) to address the preclinical aspects of inhalational medicinal products [delivery, absorption distribution metabolism and excretion (ADME), activity, toxicity].
-
Promote the Risk-Based Approach to establish the safety testing programs of inhalational medicinal products.
-
Promote common analytical approaches in toxicity assessments of inhalational medicinal products and xenobiotics.
-
Train ECIs on the toxicity assessment of inhaled medicines.